A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Kumar, Bhavna ^a,b   Yadav, Arti ^b   Hideg, Kalman ^c   Kuppusamy, Periannan ^d   Teknos, Theodoros N ^a,b   Kumar, Pawan ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PÉCS   (Hungary)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; CURCUMIN; DIARYLIDENYLPIPERIDONE DERIVATIVE; FOCAL ADHESION KINASE; H 4073; JANUS KINASE; PIPERIDONE DERIVATIVE; PROTEIN KINASE B; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; HEAD AND NECK CANCER; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MONOTHERAPY; MOUSE MODEL; NONHUMAN; PROTEIN CLEAVAGE; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL MOTION; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; HEAD AND NECK NEOPLASMS; HUMAN; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CURCUMIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HEAD AND NECK NEOPLASMS; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899834932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093208     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Sturgis EM, Wei Q, Spitz MR (2004) Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol 31: 726-733.
3. Marur S, D'Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11: 781-789.
4. Kalavrezos N, Bhandari R (2010) Current trends and future perspectives in the surgical management of oral cancer. Oral Oncol 46: 429-432.
5. Marur S, Forastiere AA (2008) Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 83: 489-501.
6. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
7. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, et al. (2008) Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 26: 3138-3146.
8. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809.
9. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, et al. (2007) Constitutively Activated Stat3 Induces Tumorigenesis and Enhances Cell Motility of Prostate Epithelial Cells through Integrin {beta}6. Mol Cell Biol 27: 4444-4453.
10. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, et al. (2000) Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97: 4227-4232.
11. Schlessinger K, Levy DE (2005) Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 65: 5828-5834.
12. Haura EB, Zheng Z, Song L, Cantor A, Bepler G (2005) Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11: 8288-8294.
13. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF (2004) Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3: 11-20.
14. Watson CJ, Miller WR (1995) Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 71: 840-844.
15. Lai SY, Johnson FM (2010) Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat 13: 67-78.
16. Niu G, Wright KL, Huang M, Song L, Haura E, et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008.
17. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, et al. (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21: 7611-7618.
18. Kim D-Y, Cha S-T, Ahn D-H, Kang H-Y, Kwon C-I, et al. (2009) STAT3 expression in gastric cancer indicates a poor prognosis. Journal of Gastroenterology and Hepatology 24: 646-651.
19. Alvarez JV, Mukherjee N, Chakravarti A, Robe P, Zhai G, et al. (2007) A STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis. Translational Oncogenomics 2: 99-105.
20. Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, et al. (2009) Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br J Cancer 101: 967-972.
21. Gu F, Ma Y, Zhang Z, Zhao J, Kobayashi H, et al. (2010) Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 23: 671-676.
22. Bourguignon LY, Earle C, Wong G, Spevak CC, Krueger K (2012) Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 31: 149-160.
23. Al Zaid Siddiquee K, Turkson J (2008) STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18: 254-267.
24. Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, et al. (2010) Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: Differential cytotoxicity in healthy and cancer cells. Free Radical Biology and Medicine 48: 1228-1235.
25. Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, et al. (2010) Anticancer Efficacy of a Difluorodiarylidenyl Piperidone (HO-3867) in Human Ovarian Cancer Cells and Tumor Xenografts. Molecular Cancer Therapeutics 9: 1169-1179.
26. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, et al. (2010) Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head & Neck 32: 417-426.
27. Kumar B, Yadav A, Lang JC, Cipolla MJ, Schmitt AC, et al. (2012) YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol Cancer Ther 11: 1988-1998.
28. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
29. Yadav A, Kumar B, Datta J, Teknos TN, Kumar P (2011) IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res.
30. Yadav A, Kumar B, Teknos TN, Kumar P (2011) Sorafenib enhances the antitumor effects of chemo-radiation treatment by down-regulating ERCC-1 and XRCC-1 DNA repair proteins. Molecular Cancer Therapeutics In press.
31. Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 75: 787-809.
32. Zhao M, Gao F-H, Wang J-Y, Liu F, Yuan H-H, et al. (2011) JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer 73: 366-374.
33. Leemans CR, Braakhuis BJM, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22.
34. Nisi KW, Foote RL, Bonner JA, McCaffrey TV (1998) Adjuvant radiotherapy for squamous cell carcinoma of the tongue base: improved local-regional disease control compared with surgery alone. Int J Radiat Oncol Biol Phys 41: 371-377.
35. Dimery IW, Hong WK (1993) Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85: 95-111.
36. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, et al. (2008) ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99: 167-172.
37. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, et al. (2002) Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62: 6659-6666.
38. Aoki Y, Feldman GM, Tosato G (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101: 1535-1542.
39. Zhang X, Zhang J, Wei H, Tian Z (2007) STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol Rep 17: 1377-1382.
40. Szakács G, Váradi As, Ozvegy-Laczka C, Sarkadi Bz (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discovery Today 13: 379-393.
41. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, et al. (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26: 3128-3137.
42. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, et al. (2003) P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25: 654-661.
43. Kumar P, Gao Q, Ning Y, Wang Z, Krebsbach PH, et al. (2008) Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone. Mol Cancer Ther 7: 2060-2069.
44. Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, et al. (2012) Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer. Clinical Cancer Research 18: 4986-4996.
45. Huang S, Chen M, Shen Y, Shen W, Guo H, et al. (2012) Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett 315: 198-205.
46. Girouard J, Lafleur M-J, Parent S, Leblanc Vr, Asselin E (2013) Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells. Gynecologic Oncology 128: 335-343.
47. Carden CP, Stewart A, Thavasu P, Kipps E, Pope L, et al. (2012) The association of PI3 kinase signalling and chemo-resistance in advanced ovarian cancer. Molecular Cancer Therapeutics.
48. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY (1996) Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134: 793-799.
49. Lim S-T, Chen XL, Lim Y, Hanson DA, Vo T-T, et al. (2008) Nuclear FAK Promotes Cell Proliferation and Survival through FERM-Enhanced p53 Degradation. Molecular cell 29: 9-22.
50. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6: 56-68.
51. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, et al. (2003) Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56: 846-853.